Not often that we see cyclophosphamide and haploidentical hematopoietic cell transplantation as the focus of a feature article in a mainstream magazine. Nice write-up in The Atlantic: CIBMTR ASH theatlantic.com/health/archive…

Just felt Philadelphia earthquake here in center city M 4.8 - 5 km NE of Lebanon, New Jersey earthquake.usgs.gov/earthquakes/ev…

It was my honor to meet with Dr Figaro and his team at Méderi Hospital in Bogota Colombia this morning to discuss the rapidly changing treatments for AML. Amazing to see our colleagues home hospital and exchange experiences treating our patients. Thank you.

Thank you for including me in this great exchange of knowledge among experts across the globe!

Happy to share the LTFU data from VIALE-A Phase III trial for Newly diagnosed AML unfit for induction. With 43.2 months follow up median OS 14.7m with Venetoclax/Azacitidine. Details of dosing adjustments in patients on therapy >6 cycles included. onlinelibrary.wiley.com/doi/10.1002/aj…

My pleasure to host rising starts in Penn Medicine - Abramson Cancer Center Heme/Onc Fellowship for journal club reviewing AGILE Ivo/aza manuscript!

UPENN recruiting Hematopathologist at Assistant Professor position. Physicians interested in joining a great team at UPENN should apply at: apply.interfolio.com/133470

Thank all who joined the second Philadelphia Leukemia rounds! Sponsored by The Leukemia & Lymphoma Society Dr. Catherine Lai & Ximena Jordan Bruno both stars of Penn Medicine - Abramson Cancer Center Leukemia program reviewed myeloid predisposition syndromes with case by 2nd year fellow Putzer Hung

I am happy to donate #MOC $ to ASH & ASCO if they supported our movement against #ABIM #MOC & #LKA beyond initial certificate. I am also happy to do CMEs (ideally 1 of 4 subspecialty tracks: Myeloid, Lymphoid, myeloma & classical #heme ) managed by #ASH . RT if agree

Such a honor to be part of the world wide community of doctors working for better outcomes here at ECHO LATAM meeting.

🧐 Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy was tolerable in patients with newly-diagnosed #AcuteMyeloidLeukemia ➡️ fal.cn/3Alen #AML #leusm